Psychedelic highlights | February 15 – 19

Shares :

Psychedelic highlights | February 15 – 19

Here is a summary of the news from the last week in the psychedelics market. The value of the psychedelics market is more than $100 billion according to Cannacord most recent report.

Psychedelic market value by company

Last week performance

CompassCMPS$53.12+ 9 %
M2Bio SciencesWUHN$0.985+ 4.9 %
MindMedMMED$5.06– 0.5 %
NuminusNUMI$1.74– 4.3 %
Psyched WellnessPSYC$0.57– 5 %
Field TripFTRP$7.50– 6.25 %
Mind CureMCUR$0.58– 8 %
Cybin Inc. CYBN$1.92– 8.5 %
Revive TherapeuticsRVV$0.59– 14.4 %
Red Light HollandsTRIP$0.51– 15 %

Story of the week

1. Revive Therapeutics Acquires Unique Psilocybin Assets [news release]

Revive Therapeutics is pleased to announce that, further to its press release dated December 21, 2020, it has entered into an asset purchase agreement (the “Agreement”) with Newscope Capital Corporation (“Newscope”) (CSE: PHRM) (OTCQB: PHRRF) to acquire the full rights to PharmaTher Inc.’s (“PharmaTher”) intellectual property (the “Acquired Assets”) pertaining to psilocybin (the “Acquisition”).

Read the full news HERE

2. MindMed’s LSD Neutralizer Study Begins and Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company [news release]

MindMed Inc. announced the start of a study for its LSD neutralizer technology intended to shorten and stop the effects of an LSD trip during a therapy session

And more, MindMed Inc. announced that it will acquire HealthMode, a digital medicine and therapeutics startup that uses Artificial Intelligence (AI)-enabled digital measurement to increase the precision and speed of clinical research and patient monitoring. 

Read the full news HERE

3. Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation [news release]

Numinus is pleased to share that the single-arm, open-label, compassionate access1 trial for MDMA-assisted therapy has made significant progress towards treating patients with posttraumatic stress disorder (PTSD).

Read the full news HERE

4. Lobe Sciences Successfully Completes Proof-of-Concept of Proprietary Nasal Mist Device [news release]

Lobe Sciences announced today the completion and testing of the proof-of-concept prototype of its proprietary nasal mist device. As announced on December 3, 2020, the Company engaged VisionWorks Engineering of San Diego, CA to complete this first phase of development.

Read the full news HERE

5. MINDCURE Announces Official Release of Nootropic and Adaptogen Products, Available on E-Commerce Platform and Engages Dr. Dan Engle as Primary Investigator for Research in Traumatic Brain Injury with Psychedelics [news release]

Mind Cure announce the release of its original nootropic and adaptogen product offerings (the “Products”). 

and more, Mind Cure’s announce the engagement of Dr. Dan Engle as Mind Cure’s Primary Investigator Consultant. Dr. Engle is Board Certified in Psychiatry and Neurology, with a clinical practice that combines functional medicine, integrative psychiatry, neuro-cognitive restoration. 

Read the full news HERE

6. Nova Mentis Expands Pre-Clinical Development Pipeline; Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug [news release]

Nova Mentis Life Science Corp. announce that the Company is expanding its pre-clinical program to develop a novel diagnostic and treatment approach to fragile X syndrome (FXS), a persistent unmet medical need. 

Read the full news HERE

7. Cybin Inc. Releases Financial Highlights and Provides Business Update [news release]

Cybin today released financial highlights from its fiscal third quarter. And as part of the ongoing Adelia Therapeutics team integration, the Company is pleased to announce the following team member appointments.

Read the full news HERE

8. Field Trip Health Ltd. Reports Third Fiscal Quarter 2021 Financial Results [news release]

Field Trip reported its third fiscal quarter results for the three and nine months ended December 31, 2020. 

Q3 2021 patient services revenues of $316,329 represent a 235% increase over the previous quarter 

Read the full news HERE

9. Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development [news release]

Entheon announce the appointment of Dr. Brian Jahns to the role of Chief Business Officer.

Dr. Jahns brings more than 20 years of business leadership and biopharmaceutical expertise to his role in overseeing the overall business development of Entheon, including the development and maintenance of strategic relationships with third parties, including regulatory authorities.

Read the full news HERE

10. Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program [news release]

Tryp Therapeutics  has begun the process of manufacturing the 200g non-GMP demonstration batch of psilocybin. This production step is one of a series of steps in the project plan to manufacture batches of Tryp’s proprietary formulation of cGMP psilocybin to support the company’s clinical development and for the company’s upcoming clinical trials..

Read the full news HERE

Sign up for MORE news updates !

This article is written and published by The Cannabis Stock

Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

Shares :